Featured/ UNCY/ 06/30/2026 · 7:34 AM Unicycive Therapeutics Receives FDA Complete Response Letter for Resubmitted OLC NDA The CRL relates to third-party manufacturing issues, but the FDA raised no concerns about clinical efficacy or safety.
